Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

01-10-2019 | Mesothelioma | Video | Article

Researcher comment: PROMISE-meso trial fails to meet primary endpoint

print
PRINT
insite
SEARCH

Sanjay Popat reports on the trial pitting pembrolizumab against chemotherapy in relapsed malignant pleural mesothelioma and outlines possible strategies for taking immune checkpoint inhibitors forward (4:53). 

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read the transcript

print
PRINT

Related content

09-10-2019 | Mesothelioma | Conference coverage | News

No survival improvement with pembrolizumab in malignant pleural mesothelioma

24-05-2018 | Mesothelioma | News

Tremelimumab plus durvalumab active in unresectable mesothelioma

01-04-2019 | Malignant pleural disease | Conference coverage | News

Mesothelin-targeted CAR T-cell therapy shows promise for malignant pleural disease

01-04-2019 | Malignant pleural disease | Video | Article

Researcher comment: CAR T-cell therapy for malignant pleural disease
Image Credits